Custom cancer vaccine shows promise in early pancreatic cancer trial
NCT ID NCT05111353
Summary
This early-stage study tested a personalized vaccine designed to teach the immune system to attack pancreatic cancer cells. The trial involved 33 patients with pancreatic cancer who had already received chemotherapy. Participants received the vaccine either before or after surgery to see if it was safe and if it triggered an immune response against their specific cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.